脑出血患者收缩压强化降压与急性肾损伤
本研究基于多中心随机试验的1000例脑出血患者数据,比较发病4.5小时内强化降压(目标110-139 mmHg)与标准降压(目标140-179 mmHg)对急性肾损伤(AKI)和肾脏不良事件的影响。结果显示AKI发生率为14.9%,肾脏不良事件为6.5%;基线血肌酐较高和尼卡地平累积剂量较高与AKI及肾脏不良事件风险增加相关,且AKI与90天死亡或残疾风险升高相关。
要点
- 脑出血强化降压患者中AKI发生率为14.9%,肾脏不良事件为6.5%。
- 基线血肌酐≥110 μmol/L和较高尼卡地平剂量与AKI风险增加独立相关。
- 发生AKI与90天死亡或残疾风险升高相关,肾脏不良事件未见此关联。
核心结论
- 脑出血患者中基线血肌酐较高和接受较高剂量尼卡地平者AKI及肾脏不良事件风险更高。
- 发生AKI与3个月死亡或残疾率升高相关,而肾脏不良事件未显示此关联。
研究设计与样本
- 多中心随机试验的二次分析,纳入1000例发病4.5小时内、初始收缩压≥180 mmHg的脑出血患者。
- 患者随机接受强化降压(目标110-139 mmHg)或标准降压(目标140-179 mmHg)。
- AKI通过随机化后3天内每日血清肌酐序列评估识别。
主要发现
- 1000例患者中AKI 149例(14.9%),肾脏不良事件65例(6.5%)。
- 基线血清肌酐≥110 μmol/L与AKI相关(OR 2.4,95%CI 1.2-4.5),与肾脏不良事件相关(OR 3.1,95%CI 1.2-8.1)。
- 尼卡地平静脉剂量曲线下面积较高与AKI相关(OR 1.003,95%CI 1.001-1.005),与肾脏不良事件相关(OR 1.003,95%CI 1.001-1.006)。
- AKI患者90天死亡风险较高(RR 2.6,95%CI 1.6-4.2),死亡或残疾风险较高(RR 1.5,95%CI 1.3-1.8);肾脏不良事件患者未见此风险升高。
临床怎么用
- 对脑出血降压治疗患者,应关注基线血肌酐水平及尼卡地平累积剂量,识别AKI高风险者。
- 监测AKI发生可能有助于评估90天死亡或残疾风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We determined the rates and predictors of acute kidney injury (AKI) and renal adverse events (AEs), and effects of AKI and renal AEs on death or disability in patients with intracerebral hemorrhage. METHODS: We analyzed data from a multicenter trial which randomized 1000 intracerebral hemorrhage patients with initial systolic blood pressure ≥180 mm Hg to intensive (goal 110-139 mm Hg) over standard (goal 140-179 mm Hg) systolic blood pressure reduction within 4.5 hours of symptom onset. AKI was identified by serial assessment of daily serum creatinine for 3 days post randomization. RESULTS: AKI and renal AEs were observed in 149 patients (14.9%) and 65 patients (6.5%) among 1000 patients, respectively. In multivariate analysis, the higher baseline serum creatinine (≥110 μmol/L) was associated with AKI (odds ratio 2.4 [95% CI, 1.2-4.5]) and renal AEs (odds ratio 3.1 [95% CI, 1.2-8.1]). Higher area under the curve for intravenous nicardipine dose was associated with AKI (odds ratio 1.003 [95% CI, 1.001-1.005]) and renal AEs (odds ratio 1.003 [95% CI, 1.001-1.006]). There was a higher risk to death (relative risk 2.6 [95% CI, 1.6-4.2]) and death or disability (relative risk 1.5 [95% CI, 1.3-1.8]) at 90 days in patients with AKI but not in those with renal AEs. CONCLUSIONS: Intracerebral hemorrhage patients with higher baseline serum creatinine and those receiving higher doses of nicardipine were at higher risk for AKI and renal AEs. Occurrence of AKI was associated higher rates of death or disability at 3 months. Registration: URL: https://clinicaltrials.gov. Unique identifier: NCT01176565.
引用
- Qureshi AI, Huang W, Lobanova I, et al. Systolic Blood Pressure Reduction and Acute Kidney Injury in Intracerebral Hemorrhage. Stroke. 2020. PMID: 32838673. doi:10.1161/STROKEAHA.120.030272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。